A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Luckily for you, StockStory helps you navigate which companies are truly worth holding. That said, here is one low-volatility stock that could offer consistent gains and two that may not deliver the returns you need.
Two Stocks to Sell:
Concrete Pumping (BBCP)
Rolling One-Year Beta: 0.81
Going public via SPAC in 2018, Concrete Pumping (NASDAQ: BBCP) is a provider of concrete pumping and waste management services in the United States and the United Kingdom.
Why Should You Sell BBCP?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 7.8 percentage points
At $7.11 per share, Concrete Pumping trades at 39.4x forward P/E. To fully understand why you should be careful with BBCP, check out our full research report (it’s free).
Tri Pointe Homes (TPH)
Rolling One-Year Beta: 0.66
Established in 2009 in California, Tri Pointe Homes (NYSE: TPH) is a United States homebuilder recognized for its innovative and sustainable approach to creating premium, life-enhancing homes.
Why Are We Out on TPH?
- Demand cratered as it couldn’t win new orders over the past two years, leading to an average 7.6% decline in its backlog
- Forecasted revenue decline of 18.5% for the upcoming 12 months implies demand will fall even further
- Earnings per share decreased by more than its revenue over the last two years, showing each sale was less profitable
Tri Pointe Homes’s stock price of $35.08 implies a valuation ratio of 12.5x forward P/E. If you’re considering TPH for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
Vertex Pharmaceuticals (VRTX)
Rolling One-Year Beta: 0.68
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Why Does VRTX Stand Out?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 16.1% annual sales growth over the last five years
- Earnings per share grew by 15.9% annually over the last five years, massively outpacing its peers
- ROIC punches in at 41.8%, illustrating management’s expertise in identifying profitable investments
Vertex Pharmaceuticals is trading at $389.01 per share, or 19.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
